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COVID-19 Coronavirus. At first seen in the Wuhan province of China, presently limitlessly 
spreading all over world. How the COVID 19 has been made on the globe become Pandemic 
needs no depiction. The virus has been accounted for affecting the lungs and related respiratory 
tracts promoting harm of the alveoli. It has been accounted that the respiratory sickness is the 
prevailing Clinical symptom of COVID-19. This review article discusses an easily understanding 
of the causes, different type of Human viruses regarded of Coronavirus, clinical diagnosis of RT-
PCR, FET, Primary prevention and control of the virus. Therefore, this review article main theme 
is to provide more reliable and valid information to control and manage public emergency in 
both acute and chronic conditions of coronavirus 
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INTRODUCTION 
In late December 2019, a bunch of pneumonia cases, caused 
about by a recently distinguished beta coronavirus, happened in 
Wuhan, China. This Coronavirus, was from the outset named as 
the 2019 novel coronavirus on twelfth January, 2020 by world 
health organization (WHO), WHO legitimately named the 
infection as Coronavirus ailment (2019) that name is COVID-19 
and Coronavirus study gathering (CSG) of the international 
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committee proposed to name the new Coronavirus as SARS-
COV-2, both gave on 11th February, 2020. The Chinese 
researchers quickly isolated a SARS-CoV2 from a patient in a 
brief time, frame on 7th January 2020 and came out with genome 
sequencing of the SARS-CoV-2 [1-4]. Coronavirus 
morphological features: Severe acute respiratory syndrome 
coronvirus-2 (SARS-CoV-2) belongs to the family of 
coronavirus. Coronaviruses (CoVs) are the largest group of 
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viruses belonging to the Nidovirales order which includes 
Coronaviridae, Atreriviridae, Mesoniviridae, Roniviridae 
families. The Coronavirinae comprise one of the two 
subfamilies in the Coronaviridae family, with the other being 
the Torovirinae [5-8]. Apart from SARS-CoV-2, there are 6 
known coronavirus in human. Coronavirus are large 
pleomorphic spherical particles with bulbous surface projection 
the diameter of the virus particles is around 120mn. The viral 
envelope comprises of a lipid bilayer layer, spike basic proteins 
are tied down, the positive-sense single- stranded RNA genome 
in a nonstop dots on a string type adaptation. The genome size 
for coronavirus ranges from around 27 to 34kb [9, 10]. To date, 
COVID-19 has spread rapidly in more than 190 countries, 
causing more than 11 million and more than 5 lakhs deaths as of 
8 July 2020. Considering the global threat, the WHO has 
declared COVID-19 a public health emergency of international 
concern (PHEIC). 
 
Table 1: Structure of coronavirus 
Structural Protein Function of Protein 
Nucleocapsid 
Protein (N) 
Bound to RNA genome to make up 
nucleocapsid 
Spike protein (S) Critically for binding of host cell receptor to facilitate entry of host cell 
Membrane Protein 
(M) 
Central organizer of CoV assembly 
Determines shapes of viral envelope 
Envelope Protein 
(E) 
Interacts with M to form viral 
envelope 
                                
Fig 1: Image of coronavirus 
 
Reference: BBc coronvirus symptoms: Ghanadan record first 
cases of COVID-19 from Google images 
 
Stages of corona viruses:  
In general, there are four stages of COVID-19 
Stage 1: Imported cases: When the cases of an infection are 
important into a country, which was not the source of the 
infection. 
Stage 2: Locally transmission: When the virus is locally 
transmitted in the country. It means the person from whom the 
virus spread to the other one is from the country itself. 
Stage 3: Community transmission: In this stage, the virus has 
started circulating in the community. Here it becomes very tough 
to track the chain of transmission of the virus. In this stage a 
lockdown becomes very need. 
Stage 4: Epidemic: When the infection becomes Endemic. 
Table 2. Human corona virus [10] 
Virus Genes Disease Discovered 
CoV-
229E Alpha 
Mid respiratory tract 
infection 1967 
CoV-
NL-63 Alpha 
Mid respiratory tract 
infection 1965 
CoV-
HKU-1 Beta 
Mid respiratory tract 
infection pneumonia 2005 
CoV-
OC43 Beta Mid respiratory  2004 
SARS-
CoV Beta 
Human severe acute 
respiratory syndrome, 
10% mortality rate 
2003 
MERS-
CoV Beta 
Human severe acute 
respiratory syndrome 
37% mortality rate 
2012 
 
Methods: [11] 
 Study design: A scoping reviews was conducted by different 
methodological frameworks. Generally 5 stages followed for 
conducting this scoping review include 1) Identification of clear 
research objective and search strategies, 2) Identifying relevant 
research, review and short communication articles, 3) Selection 
of relevant research, review and articles, 4) Extraction and 
charting of data, 5) Summarizing, discussing, analyzing and 
reporting the results. 
 
Literature search strategies: Literature for the review was 
identified by searching the following online databases like 
Google scholar, Google search, Pubmed, as well as other reputed 
research, review and short communication, maximum these 
complete online databases and information contains archives of 
English and some are Chinese biomedical and also Indian 
journals. The search terms were novel corona virus, 2019, 
Pneumonia, respiratory diseases, COVID-19. 
 
Identification, Selection and data extraction from the 
studies: After the articles were selected, data were extracted and 
recorded in proper manner by using word and Excel spread 
sheet. The extracted data were date of publication, Language of 
publication, name of journal, title of article, divide research and 
review article, author's country and affiliation etc. 
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Summarizing: Based on the main research objectives, article 
were classified into one of the following research domains: 
epidemiology, pathophysiology, causes, clinical symptoms, 
transmission, diagnosis, prevention and management. A 
publication was considered also based on country, Authors 
Journal name, publication dates, language etc. as well as 
methodological characteristics were analyzed respectively. All 
findings and statements that are mentioned regarding the 
outbreak in this review are based on published information as 
listed in the references. 
 
Life cycle of coronavirus: [11, 12] 
Life cycle of coronavirus has 4 steps of viral life in human. 
1. Attachment and entry  
2. Transmission of replicase gene from viral RNA  
3. Replication and transcription  
4. Assembly and release 
 
1) Attachment and entry: The connection of the virus to the 
membrane is begun cooperation between two components i.e. S 
protein and its receptor. S protein contain the receptor binding 
domin (RBD) on which the virus connects first. The virus have 
section into the cytosol, thus it perform following activities. 
1) Cleavage of S Protein  
2) This cleavage exposes the fusion peptides 
3) The two heptide will join to S2 site 
4) This will form the bundle 
5) The bundle pack is liable for the mixing of the viral and 
cellular membrane then the fusion of the membrane occurs 
6) Finally the infection of virus will discharge its viral genome 
into the cytosol of the cell. 
 
2) Transmission of replicate gene from viral RNA: [11, 12] 
Replicate gene encoded two enormous ORES which are rep1a 
and rep1b that are answerable for the coding of two proteins that 
is pp1a and pp1ab. To communicate this two proteins, the virus 
need to utilize slippery sequence and pseudoknot which is liable 
for ribosomal frameshifting. For the most part ribosome loosen 
up the Pseudoknot and proceed with the interpretation until stop 
codon shows up to stop the procedure. In some cases the 
pseudoknot stops the ribosome for the translation process which 
results in frameshifting of ribosomes. Polyprotein contains 
NSPS 1-11 and 1-16. Numerous NSPS accumulates into 
replicate transcription complex (RTC) to make a situation which 
is useful for RNA synthesis. This outcomes in replication of 
RNA and sub-genomic RNA transcription. 
 
3) Replication and transcription: 
RNA synthesis produces genome RNA and sub-genomic RNA. 
This sub- genomic RNA GI about as m-RNA for both auxiliary 
and adornment genes. Genomic and sub-genomic RNA are 
delivered through negative strand mediate. 
 
4) Assembly and release:  
In the wake of shaping sub-genomic RNA Union and replication, 
the basic proteins i.e., S, M, E and N are first made an 
interpretation of and afterwards embedded into the endoplasmic 
reticulum. This protein moves towards endoplasmic reticulum 
golgi middle compartment. At this site the develop virus are 
shaped and gathered. This recently formed viruses then got 
discharge from the cell to deliver more viruses. 
 
Incubation period of the virus on different surfaces:  
The coronavirus is very sensitive it can live in air up to 3 hrs. 
Table: 3 Incubation period of the virus on different surfaces 
[13] 
Surface type Incubation period 
Air 3hrs 
Copper 4hrs 
Card board 24hrs/1day 
Plastic material 48-72 hrs 
Stainless steel 48-72hrs 
 
Etiology and pathogenesis of COVID-19 [14,15,18] 
COVID-19 virus SARS-COV-2 is 7th individual from the group 
of CoVs that infect people but four CoVs (HCoV-229E, HCoV-
NCG3, HCoV-OC43, and HCoV-HKU1) can cause a wide 
scope of upper respiratory tract diseases i.e. normal cold, though 
MERS-CoV and SARS-COV are answerable for a typie 
pneumonia. The reasons for various disease locals are likely 
identified with the nearness of Dipeptidyl peptidase 4 (DPP4) 
and angiotensin converting enzyme (ACE2) in the lower 
respiratory tract. Which are the major human receptors for the 
surface spike(S) glycoprotein of MERS-CoV and SARS-COV 
respectively. The hereditary succession of SARS-COV-2 is 70% 
like that SARS-COV and SARS-COV-2 is equipped for utilizing 
a similar cell entry receptor as SARS-COV to taint people. In 
any case, there are more contrasts in the keys protein that the 
infections use to associate with have cells. SARS-COV-2 spike 
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tie to human ACE2 with roughly 10-20 crease higher partiality 
than the SARS-COV spike, making it simpler to spread from 
human to human. Upon entry into alveolar epithelial cells, 
SARS-COV-2 replicates quickly and triggers a strong immune 
response, bringing about cytokine storm conditions and 
pulmonary tissue harm. Investigation of the initial 99 confirmed 
cases of SARS-COV-2 infection uncovered that storm syndrome 
happened in patients with extreme COVID-19. 17% patients had 
ARDS, among whom 11% deteriorated within a short period of 
time and died of numerous organ failure. Moreover, the number 
of total CD4+ T-Cells, CD8+ T-cells and T-Cells are diminished 
in patients suffered with SARS-COV-2 infection, and the 
enduring T-Cells are practically depleted, recommending a 
diminished immune capacity in SARS-COV-2 infected patients. 
 
Transmission route of SARS-COV-2 [16-18] 
The novel CoV can be transmitted between people by means of 
respiratory beads. Eminently the respiratory tract is most likely 
by all account not the only route of human to human 
transmission soon assumed the primary form of diffusion. 
Human transmission occurred among family members, 
including friends and close relatives. Local authority people and 
other professional, including health care workers also source of 
transmission of SARS-COV-2. COVID-19 can be transmitted 
through direct or indirect contact with eye, mouth or nose mucus 
membrane. There is likewise a chance of vaporized or aerosol 
transmission in a continuously exposure to high concentrations 
of aerosol. In addition, it has been accounted for that SARS-
COV-2 patients have some GIT symptoms, including the nausea, 
vomiting, diarrhoea. An ongoing report demonstrated that the 
enteric clinical symptoms of COVID-19 are related with 
attacked ACE2 communicating enterocytes, proposing that the 
stomach related tract is an expected route of COVID-19 
infections other than the respiratory tract, so that as it may 
require extra examination to test this Chance. Furthermore, 
regardless of whether transmission of SARS-COV-2 can happen 
by mRNAs of breastmilk or vertically from mother to newborn 
child has not been resolved. 
 
Symptoms [19] 
Maximum of the patients infected with the coronavirus will 
encounter normal cold and flu, 80% of patients will show mild 
symptoms of this COVID-19 diseases. Adult have the best 
immunity power to fight against the infection but the demerit is 
that they are more likely to spread the infection of virus.99% of 
the patients built up fever with very high temperature, while the 
greater part experienced fatigue and dry cough and trouble in 
breathing. Maximum of patients have infected extreme cases and 
remaining have become critically ill. Step by step breakdown of 
Corona virus symptoms, how indications progress among 
typical patients and how the disease COVID-19 goes from 
terrible to worse are given below  
 
Day 1: In the beginning day of the side effects, the patient 
experiences fever along with fatigue, muscle torment and a dry 
cough. Not many of them may encounter sickness and loose 
bowels a couple of days before the excitement 
Day 5: Patients may experience the ill effects of breathing issue 
particularly in the event that they are older or have some prior 
wellbeing condition. 
Day 7: According to the Wuhan university study, these are the 
side effects of the patient that lead the patient to be conducted in 
the clinic. 
Day 8: Patients develop acute respiratory distress syndrome 
(ARDS), a condition where the liquid fills up in the lungs and 
this is mostly fatal. This typically occurs in serious cases. 
Day 10: The movement of the ailment prompts intensifying of 
the indication and now the patients is moved to ICU. Patients 
with milder symptoms most likely have progressively stomach 
pain and loss of appetite only a small fraction die. 
Day 17: On average, after nearly 18 to 19 Day s patients who 
recover, are discharged from the hospital however, it’s difficult 
to find out the symptoms in the earlier Day s of the infection. 
This is generally observed following 5-6 days. 
 
General symptoms: Fever, chest pain, weariness, loss of smell 
and taste, dry cough, dysponea. 
Less symptoms: cerebral pain, stomach torment, looseness of the 
bowels, vomiting, dizziness. 
Severe complication reported among COVID-19 patients: 
Hypoxemia, ARDS, Arrhythmia, Shock, Acute cardiac injury 
and acute kidney injury. 
 
Diagnosis [20-22] 
As the coronavirus that causes the COVID-19 malady spreads 
over the world, for the identification of viruses use real time 
reverse transcription polymerase chain reaction (RT-PCR). The 
real time RT-PCR one of the most precise research facility 
technique for identifying, tracking and contemplating the 
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coronavirus and also Field-effect transistor (FET) biosensing 
device. 
Fig 2: Image of coronavirus symptoms 
 
Ref: Time magazine corona virus questions and answered: we 
know about COVID-19 from Google images 
 
What is real time RT-PCR? 
For recognizing the presence of explicit hereditary material from 
any pathogen, including a virus the real time RT-PCR technique 
is utilized. In this strategy radioactive isotopes markers are 
utilized to identify and focused on hereditary materials, however 
ensuring refining has prompted the supplanting of the isotopic 
naming with unique markers, most much of the time fluorescent 
colors. This strategy is the choice for diagnosis of human CoV, 
as multiplex real time RT-PCR assays have been created. They 
can recognize each of the four respiratory HCoVs and could be 
additionally adjusted to novel CoVs. Serologic examines are 
significant in case of RNA maybe very hard to isolate and it is 
no longer present in for epidemiogical studies. It was 
recommended by the Chinese centre for disease control and 
prevention to utilize groundworks and tests like ORF1ab and N 
gene regions for the detection of SARS CoV-2 by RT-PCR. 
 
Why use real time RT-PCR? 
1) This method is profoundly delicate and explicit. 
2) It can deliver a reliable identified as quickly as 3 hours. 
3) It is essentially quicker than the other methods which 
utilized for the Isolation of virus. 
4) This method has a lower potential for contamination or 
mistakes as the whole procedures should be done with in a 
closed tube. 
5) It keeps on being the most exact technique available for 
detection of the COVID-19 viruses. 
6) Different techniques for determination like CT check, High-
throughput sequencing also been suggested by different 
health authorities. 
 
Field-effect transistor (FET) biosensing device [23] 
Field-effect transistor (FET)-based biosensing device for 
detecting SARS-COV-2 in clinical samples. The sensor was 
produced by coating grapheme sheets of the FET with a specific 
antibody against SARS-COV-2 spike protein. The performance 
of the sensor was determined using antigen protein, cultured 
viruses and nasopharyngeal swab specimen from COVID-19 
patients. This FET device could detect the SARS-COV-2 spike 
protein at concentrations of 1fg/ml clinical transport medium. 
Moreover, the FET sensor successfully detected SARS-COV-2 
in culture medium and clinical samples. This device is a highly 
sensitive immunological diagnostic method for COVID-19 that 
require no sample pretreatment or labeling. 
 
Importance of preventive care in Corona virus patients 
Primary prevention [24-26] 
1) Wash your hands frequently for at least 20sec at a time with 
warm water and soap. 
2) Don't touch or contact your eyes, face, nose or mouth when 
your hands are grimy. 
3) Don't go out in case you're feeling wiped out or have any 
cold, flu signs and manifestations. 
4) Cover your mouth within your elbow at whatever point you 
cough or sneeze. 
5) Clean any objects you touch a lot. Use disinfectant on 
objects like mobiles, laptops, keys, utensils, dish ware, 
doorknobs etc. 
6) Avoid public gatherings, strict hygiene measures for the 
control of infection. 
7) Health care personnel's must use personal protective masks 
like N95 masks, FFP3 masks, gowns, gloves etc. 
 
Screening and quarantine [24-26] 
1. One of the most significant undertaking is to screen the 
people originating from the endemic territories by checking 
their temperature, signs and manifestation of virus infection. 
2. Furthermore, posing inquiries from them about their travel 
history and any sort of contact with the infected people. 
3. There is another idea of collective screening of travelers 
going through aircrafts after leaving the endemic zones and 
showing up in some other city/ nation. Despite the fact that 
this activity has still not been productive and there are odds 
of missing over half of the cases of COVID-19, explicitly 
the ones who were demonstrating no side effects due to 
experiencing an incubation period. 
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4. In certain countries , isolate of effectively recognizable 
people wish signs and symptoms of COVID-19 was done 
strongly to prevent the further spread of the illness yet the 
mighty isolate may have ever enduring repercussions with 
psychosocial impacts. 
 
Surface Disinfectant [27] 
Surface are the most prone site for the transmission of corona 
virus infection from one to another. Depending upon the nature 
of surface, temperature, pH, and relative humidity of the 
surrounding, virus survive time different from 1-9 days. Use 
disinfectants highly risk exposed surface areas. Currently, the 
United States environmental protection agency (USEPA) 
recommended some disinfectants against COVID-19. 
 
Table 4: List of different surface disinfectant with 
composition and surface contact time [18, 27] 
Active ingredient Composition Contact time/min 
Hydrogen Peroxide Hydrogen peroxide: 0.5% 05 
Octanoic acid Octanoic acid: 5-10% 02 
Sodium Chloride Sodium chloride: 30.5% 10 
Ethanol 
Ethanol: 15-30%, 
Butane:15-32%, 
Propane:5-10% 
0.5 
Silver ion, Citric 
acid 
Silver ion: 0.003% 
Citric acid: 4.846% 01 
 
Hand Hygiene: [28-30] Human to Human transmission is a 
major part so frequent washing with soap and water or alcohol 
based sanitizer as recommended by WHO. Hand sanitizer may 
play a substantial role in providing effective hand hygiene  
 
Table 5: List of different Hand sanitizers with brand names 
and composition [18, 28-30] 
Brand Component Country 
Lifebuoy Ethyl alcohol 95%, Isopropyl alcohol 
10%, Tocopheryl acetate0.05%, 
Perfume gel base 109% 
India 
Himalaya Dhanyaka 0.30mg, Ushira 0.30mg, 
Nagaramusta 0.25mg, Shati 0.10mg, 
Nimba 0.05mg 
India 
Savlon Ethanol IP 66.5%v/v, Isopropyl 
alcohol IP3.5%v/v, Permitted colors 
used, Gel based Q.S 
India 
Zuci Strawberry extract, salicylic acid, 
Vitamin E 
USA 
3M Chlorohexidine, Gluconate 0.5% 
w/v, Ethyl alcohol IP70%v/v 
USA 
 
Face masks: [18, 27] 
Corona virus maybe an airborne infection transmitted through 
respiratory droplets. Droplets transmitted up to 1meter from who 
are diagnosed with coughing and sneezing. Different masks are 
available in the global market like dust masks, paper mask, cloth 
mask, face mask, surgical mask, N95 mask, laser mask etc. An 
ideal mask must be built with soft smooth material with 
characteristics features like protection against the microbes and 
infected droplets. The technical parameters like sub-micron 
particulate filtration efficiency (%), bacterial filtration efficiency 
(%), and breathing resistance may play key role in the choosing 
of mask. USA center for disease control and WHO recommends 
N95 or P100 respirators with 3 level protection FFP1, FFP2, and 
FFP3 against COVID-19 infection as they filter out 99.9% of 0.3 
micron particles. 
 
The US National Institute for Occupational safety and Healthy 
(NIOSH) classifies particulate filtering mask or filtering face 
piece respirators (FFRs) into 9 categories as N95, N99, N100 (N: 
not resistant to oil), P95, P99, P100(P: Somewhat resistant to oil) 
R95, R99, R100(R: Strongly resistant to oil) whereas 95,99,100 
indicates filter's minimum filtration efficiency with 95,99 
&99.97% respectively. According to the European Standard 
(EN149:2001), FERs are categorized into FFP1, FFP2 & FFP3 
with minimum filtration efficiencies of 89, 94, 99% respectively. 
 
Gloves [18, 31] 
Contaminated hands share a major contribution to the 
spreadability of corona virus infection. Generally maximum 
people touch their faces frequently. The use of nitrile gloves is 
preferred over latex gloves because they resist some chemicals, 
including certain disinfectants but latex gloves shows a high rate 
of allergic reactions. Non powdered gloves are preferred over 
powdered gloves as powder that is corn starch, lycopodium 
powder and talc initiate the skin irritation resulted in allergic 
reaction on prolonged usage. 
 
Face shields or Goggles  
Eye mucus is a comfortable site for virus sustainability so as per 
WHO to wear a protective transparent glass, Zero power, face 
shield that covers from all sides with adjustable holder or elastic 
rubber band. As per the European standard directive 86/ 686/ 
EEC, EN166/2002 and ANSI/SEAZ 87.1-2010, an effective 
goggles or face shield is manufactured from acetate, propionate 
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and polycarbonate that offers improved visual clarity and optical 
quality with the potential for less eye strain. 
 
General medication [32, 33] 
Suspected and affirmed cases ought to be treated in assigned 
hospital with effective isolation, protective conditions. 
Suspected cases should be treated in a separate room and 
isolated, and confirmed cases can be treated in the same ward in 
addition critical cases necessary to be admitted to the emergency 
care unit as soon as possible. Quick intervened consideration 
required for COVID-19, patients with WOB or SOB, constant 
torment or pressure in chest, new disarray or failure to excite, 
somewhat blue lips or face. 
 
Allopathic medication [18, 34] 
Allopathic medication and management involve oxygen therapy, 
I.V fluid infusion with life support in serious cases. Antiviral 
medicines such as ganciclovir, ribavirin, nelfinavir, remdesivir, 
arbidol, oseltamivir, galidesivir are being examined for COVID-
19 medication. The broad range of spectrum antibiotics maybe 
used to control the additional bacterial infections after a virus 
attack. Some drugs are under clinical trials and remaining 
approved by DCGS. The best approaches to fight with viruses is 
vaccination. Therefore, scientists are trying to develop a vaccine 
for this virus and probably maybe available after sometime. 
 
Ayurevedic, Unani and Homeopathy medication [18, 34]  
Basically, both ayurevedic and unani are plant based medicines 
which are nontoxic and without any side effects. Most of the 
plant shows Antiviral activities for a long time. The most 
important plants are Curcuma longa, Allium sativum, Ocimum 
sanctum, Piper nigrum, Cinnamomum verum, Glycyrrhiza 
glabra, Caucus maritimus etc. Therefore, an aqueous extract of 
these plants along with other plants as mentioned above along 
with other plants as mentioned above maybe useful to prevent 
and management of COVID-19. The Government of India and 
Minister of AYUSH department encouraged Indian Traditional 
medicine practices. In Homeopathy, Arsenic at very low 
concentration is considered beneficial for several diseases 
including viral infections. 
 
Immunity boosters [18, 35, 36]  
It is seen that early deaths were in older people, presumably as a 
result of the poor immunity, which forces quicker advancement 
of COVID-19. Therefore, it is noteworthy to boost our immunity 
system. It is very important to suggest that people use a few 
enhancement or supplements to boost their immune system. 
Healthy people should take a lot of citrus fruits (Lemons, 
oranges) having different nutrients and vitamins D. Some dry 
fruits such as walnuts, dates, almonds are additionally helpful to 
improve the immune system. However, the patients may take 
Zinc supplements and vitamins with the counsel of clinical 
experts. It is too savvy not to smoke and other narcotic products. 
Continuously a satisfactory rest is fundamental to support up the 
insusceptible. Immune system maintain distance and do proper 
and normal exercises. 
 
Convalescent plasma therapy [37, 38] 
It is derived from the patients with antibodies against 2019-
nCoV can be effective in reducing the mortality rate of serious 
ill patients. It has been found to have an immunotherapeutic 
potential for the treatment of SARS, MERS. The efficacy of 
Convalescent plasma therapy is that antibodies from 
convalescent might suppress viremia through free viral 
clearance, blockade if new infection, as well as the acceleration 
of infected cell clearance. In addition, the use of convalescent by 
WHO under Blood regulators network when vaccine and 
antiviral drug was unavailable for an emerging virus. This 
therapy is not associated with the occurrence of adverse events. 
It should be used for the treatment of critically I'll patients with 
COVID-19 after the evaluation of the valence of antibody. It is 
worthwhile to test the efficacy and safety of convalescent plasma 
transfusion in COVID-19 patients. 
 
Fig 3: Image of Reduce risk of COVID-19 
 
Ref: Image collected from Google images search 
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Ongoing Clinical trials [22] 
Most of the agents under trial are repurposed for the current 
COVID-19. Concurrently, several trails were initiated to test the 
specific vaccines and antibodies specifically targeting SARS- 
CoV-2. As of April 2020-291 active clinical trailed found 
specific to COVID-19 of these 291 trails 109 trails included 
Pharmacological therapy for the treatment of COVID-19 in adult 
patients of these 109 trails 82 international studies and 27 
Placebo's controlled trails. 
 
Table 6: Drugs and undergoing clinical trials and testing [22] 
Drugs Under clinical trials and testing 
Interferons Activate cytoplasmic enzymes affecting 
viral mRNA translation and protein 
synthesis 
Interleukin-2 It shows mitigating activity 
Immunoglobulin It contains vague antibodies it squares 
viral Fc receptor initiated by boosting 
endogenous killing antibodies and 
forestalling immunized subordinate 
improvement of contamination. 
Danoprevir Hepitatis C virus NS3 protease inhibitor 
that to be used in combination with 
ritonavir 
Remdesivir It is a nucleotide analogue which is use to 
treat Ebola and Marburg virus .it was also 
effective against SARSCoV-1 and MERS 
Favipiravir Inhibitor of viral RNA dependent RNA 
polymerase which can be used in treating 
influenza and inhibiting polymerase of 
other viruses like Ebola, yellow fever 
 
COVID-19 Vaccine Race 
Now, Vaccines are not available in the market, but preparation 
of vaccine against COVID-19 is under process and it may take 
more than 10 months for the initial sample to get accessibility in 
the open market. The development of vaccine represented a 
more long term strategy to prevent COVID-19 outbreaks in the 
future. With the sequencing of SARS-CoV-2 genome, numerous 
nucleic corrosive bases immunization up and comer have been 
proposed generally dependent on the S protein coding 
arrangement. 
 
1. COVAXIN [39] India’s first potential COVID-19 vaccine has 
been given approval for Phase I and Phase II clinical trials. 
Named COVAXIN™, the vaccine was developed by Bharat 
Biotech and has been granted approval from the Drugs 
Controller General of India (DCGI). Human clinical trials are 
scheduled to start across India in July 2020. Bharat Biotech 
created COVAXIN in collaboration with the Indian Council of 
Medical Research (ICMR) and National Institute of Virology 
(NIV). According to the company, the SARS-CoV-2 strain was 
isolated in NIV, Pune and transferred to Bharat Biotech. The 
indigenous, inactivated vaccine was developed and 
manufactured in Bharat Biotech’s facility located in Hyderabad, 
India. The DCGI granted permission to initiate Phase I and II 
human clinical trials after the company submitted results 
generated from pre-clinical studies, demonstrating “promising” 
and “extensive” safety and immune responses. 
2. mRNA-1273: means Moderns m RNA-1273 is a synthetic 
strand of mRNA created by Massachusetts based US Company. 
Expected to elicit antiviral response specifically towards the 
spike protein of SARS-CoV-2. Unlike conventional vaccine, 
does not require the virus. Therefore it is relatively safe and 
ready to be tested. If mRNA-273 proves to be safe for humans 
and pass the phase- I trail, successive evaluation of its efficacy 
will be carried out immediately. 
3. INO-4800:  A DNA immunization applicants made by Inovio 
Pharmaceuticals, a US based organization. Contrasted with 
ordinary antibody, Genetic vaccine requires lower costs of 
creation and simpler method of cleansing. At present is in Phase-
I clinical testing in the US for COVID-19 and and could 
potentially advance to phase 2 or 3 efficacy trails this midyear. 
4. ChAdoX1nCoV-19: Created by the University of Oxford 
composed of non-replicating adenovirus vector and the genetic 
sequence of the S protein of SARS-CoV-2. Entered phase1/2 
clinical trails the non- relatively safe in children and individuals 
with underlying diseases if the vaccine is shown to be safe and 
effective in these earlier trails, vaccine manufacturing will be 
increases to allow larger studies to take place. 
5. BCG vaccine: The Bacillus Calmette GUERIN live 
constricted antibody applicant is in the phase 2 or 3 and is 
utilized against tuberculosis to support the insusceptible 
framework. Clinical trials are being conducted to test the 
efficacy and safety of this vaccine candidate in protecting people 
against COVID-19 [40] 
6. BNT 162 SARS-COV-2 vaccine [41] BioN Tech's BNT162 
Vaccine Candidates are being developed to prevent COVID-19 
disease infection. The BNT162 program is evaluating at least 
four experimental vaccine, each of which represents a unique 
combination of mRNA format and target antigen.BNT162b1 
and BNT162b2 are both nucleoside-modified RNAs, BNT162b1 
encodes an optimized SARS-COV-2 receptor-binding domain 
(RBD) antigen, while BNT162b2 encodes an optimized SARS-
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COV-2 full-length spike protein antigen. On July 13, 2020 Pfizer 
Inc and BioNTech SE announced that 2 of the company's four 
investigational vaccine candidates from their BNT162 mRNA 
based vaccine program (BNT162b1 & BNT162b2) received Fast 
Track designation from the U.S.FDA. These vaccine candidates 
in the BNT162 program are currently being evaluated in ongoing 
phase 1/2 clinical studies in the USA and Germany. 
7. NVX-CoV2373 [42, 43] SARS-COV-2 subunit vaccine 
(NVX-CoV2373) constructed from the full- length S-Protein 
and produced in the established Sf9 insect cell expression 
system. A stable S- protein structure generated by mutating the 
furin cleavage site to be resistant to cleavage and utilization of 
two proline substitution at the apex of the central helix. NVX-
CoV2373 with matrix-M adjuvant in a non-human primate 
induces a Th1 dominant B and T- cell response, hACE2 receptor 
blocking antibodies and SARS-COV-2 neutralizing antibodies. 
A Phase 1 Clinical trials of NVX-COV2373 initiated in 
Australia during May 2020, with preliminary immunogenicity 
and safety results expected in July, 2020.The Phase 2 portion to 
assess immunity, safety and COVID-19 disease reduction is 
expected to begin thereafter. On July 7, 2020, NoVaVax, Inc. 
announced that vit has been selected to participate in operation 
warp speed, including a pivotal Phase3 clinical trials, establish 
large-scale manufacturing and deliver 100 million doses of 
NVX-CoV2373, NoVaVaX COVID-19 vaccine candidate, as 
early as late 2020.  
 
There are over a 100 vaccines being developed world wide and 
at least 30 clinical attempts in India. ICMR has joined force with 
Oxford University to create up to 60 million doses of potential 
vaccine, has effectively reported an exploration collaboration 
with Hyderabad based Bharat Biotech International Ltd (BBIL) 
to build up a COVID-19 vaccine. Additionally, the serum 
Institute of India (SII) which is the world's biggest creator of 
antibody vaccine by volume, has banded together with Oxford 
University to produce up to 60 million doses of vaccine. The 
name of the Universities and research organization who are 
continuously doing research to discover the cure for COVID-19 
[22] 
1. GSK (Glaxosmithkline)   
2. Novavax US based company 
3. Altimune 
4. Moderna – US biotech firm 
5. Curevac – A German company 
6. Imperial college – London 
7. Inovio – US biotech 
8. Zydus Cadila 
9. Vaxart 
10. Vaxil bio 
11. Bharat Biotech 
12. Oxford University 
 
CONCLUSION 
The world is currently facing a health care crisis in form of 
Novel COVID -19. Its prevention is truly crucial because it is at 
community level right now. We summarized this review by 
fundamentally analyzing all the mini review, review, short 
communication and research articles with respect to the COVID-
19. This review aims to provide the better understanding about 
the evidence of early findings on the signs and symptoms, 
implementing the public health strategies like hygiene of people 
hands, using masks, isolating the positive patients. Still there is 
no clinical treatment for novel coronavirus. The scientists are 
still attempting to discover proficient remedial designs for 
rewarding the novel coronavirus. This review helpful to the 
future researchers by providing reliable data about novel corona 
virus and also useful to Pharmaceutical Divisions and wellbeing 
crisis. 
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